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Abstract
Background—Our laboratories forged the concept of macrophage delivery of protein
antioxidants to attenuate neuroinflammation and nigrostriatal degeneration in Parkinson’s disease
(PD). Notably, the delivery of the redox enzyme, catalase, incorporated into a polyion complex
micelle (“nanozyme”) by bone marrow-derived macrophages protected the nigrostriatal against 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication. Nonetheless, how macrophage
delivery of nanozyme increases the efficacy of catalase remains unknown.
Methods—Herein, we examined the transfer of nanozyme from macrophages to brain
microvessel endothelial cells, neurons and astrocytes.
Results—Facilitated transport of the nanozyme from macrophages to endothelial and neural
target cells occurred through endocytosis-independent mechanisms that involved fusion of cellular
membranes; macrophage bridging conduits; and nanozyme lipid coatings. Nanozyme transfer was
operative across an artificial blood brain barrier and showed efficient reactive oxygen species
decomposition.
Conclusion—This is the first demonstration that drug-loaded macrophages discharge particles to
contiguous target cells for potential therapeutic brain enzyme delivery. The pathways for drug
delivery shown may be used for the treatment of degenerative disorders of the nervous system.
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Alzheimer’s and Parkinson’s diseases (AD and PD) are amongst the faster growing
disorders in disease prevalence and incidence for the 21st century. The need to develop
neuroprotectants and to control neuroinflammation for protection of the brain against injury
cannot be overstated [1–3]. To this end, we developed cell based drug delivery systems that
uses mononuclear phagocytes (MP; monocytes and macrophages) loaded with an
antioxidant enzyme, catalase, to abrogate disease-linked oxidative stress [4, 5]. Block
ionomer complexes were used to preclude enzyme degradation with catalase packaged into
particles of nanoscale size and termed “nanozymes.” We demonstrated that these nanozymes
when loaded into bone marrow-derived macrophages (BMM) abrogate inflammation and
neurodegeneration in laboratory and rodent models of human PD [4, 5]. Positively-charged
block copolymers, polyethyleneimine-poly(ethylene glycol) (PEI-PEG) and poly(L-lysine)-
poly(ethylene glycol) proved superior for enzyme delivery and demonstrated limited
cytotoxicity with optimal loading, release and enzyme activity preservation inside cells [6].
Nanotoxicology must be a consideration in the development of any inflammatory-response
cell based drug delivery system. Although monocyte-macrophages (MDM) are readily
attracted to sites of disease pathology by chemokines, the same cells are known to release
reactive oxygen species (ROS) and other cytotoxins. Indeed, a range of therapeutic
strategies for neurodegenerative disorders are based on attenuating neuroinflammatory
responses and macrophage infiltration to sites of tissue injury [7]. Although studies so far
have not reported any cytotoxic effects secondary to macrophage-mediated nanoparticle
drug delivery translation of such recent inventions to clinical practice have not yet occurred.
Encouraging data obtained from rodents demonstrate, on the contrary, that administration of
macrophages loaded with catalase nanozyme diminish micro- and astro- gliosis in mouse
models of neurodegenerative disorders [5].
The high efficacy achieved is likely linked to brain targeting in the abilities of BMM loaded
with nanozyme to cross the blood brain barrier (BBB) and release catalase at the site of
disease (particularly, in substantia nigra pars compacta, SNpc). Nanozymes are slowly
released from BMM in blood with subsequent enzyme delivery to effected brain regions.
Moreover, BMM-released catalase in the reticuloendothelial system (liver and spleen)
suppress peripheral leukocyte activation decreasing the ingress of inflammatory responses in
the brain and increasing protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)-induced neurodegeneration [5]. Here we report an as yet undisclosed pathway for
intercellular transport of nanozyme from BMM to contiguous neural cells including brain
microvessel endothelial cells (BMVEC), neurons, and astrocytes. The nanozyme transfer
from macrophage to the recipient cells was significantly greater when neural cells were
incubated directly with the nanoparticle. Facilitated macrophage-mediated nanozyme
transport involved direct nanozyme transfer from BMM to its target cells through partial
transient fusion of cellular membranes, formation of macrophage bridging conduits,
microtubules, and nanozyme lipid coatings from cell-carriers that increased cell
membranotropic properties and permeability. Such biological properties for nanozyme cell
transfer can facilitate BBB penetration, affect efficient reactive oxygen species (ROS)
decomposition in activated macrophages and increase subsequent neuronal survival. The
data taken together support the importance of macrophage-based nanozyme carriage for
neurodegenerative diseases, and notably PD.
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1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine perchlorate (DID) and 3,3'-
dilinoleyl-oxacarbocyanine perchlorate (DIO) were purchased from Invitrogen (Carlsbad,
CA, USA). Lipopolysaccharides (LPS), Sephadex G-25, Triton X-100, and trypsin, were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Catalase from bovine liver
erythrocytes was provided by Calbiochem (San Diego, CA, USA). Methoxypolyethylene
glycol epoxy (Me-PEG-epoxy) was purchased from Shearwater Polymer Inc. (Huntsville,
AL, USA). Polyethyleneimine-poly(ethylene glycol) (PEI (2K)-PEG (10K)) was
synthesized as described [4] by conjugation of PEI and Me-PEG-epoxy. Interferon gamma
(IFN-γ) was purchased from Peprotech Inc. (RockyHill, NJ, USA). 3H-labeled catalase was
custom-synthesized by PerkinElmer Life (Boston, MA, USA).
Catalase Nanozyme
The polycomplex was produced by mixing catalase and a block copolymer, PEI-PEG, which
form nanoparticles with an enzyme-polyion complex core and PEG corona [4, 5]at charge
ratio (Z = 1). This was calculated by dividing the amount of aminogroups in the block
copolymer protonated at pH 7.4 [8] by the total amount of Gln and Asp in catalase.
Cells
Bone marrow-derived macrophages (BMM) were extracted from femurs of C57Bl/6 male
mice 6 – 7 weeks of age [9] and cultured for 10 days in Dulbecco’s Modified Eagle’s Media
(DMEM) (Invitrogen, Carlsbad, CA, USA) supplemented with 1,000 U/mL macrophage
colony-stimulating factor (MCSF), a generous gift from Pfizer Pharmaceuticals, Cambridge,
MA, USA). Human monocytes were obtained from leukopaks of healthy donors, purified by
countercurrent centrifugal elutration [10] and cultured in DMEM, 1000U/mL MCSF, 10%
pooled human serum, 5mL 200mM L-glutamin, 2mL 50 mg/mL gentamicin, and 10ug/mL
ciprofloxacin.
To evaluate the macrophage-mediated transfer of nanozyme across the BBB in vitro, cell
monolayers that exhibit specific characteristics of a mature BBB (i.e. tight junctions, drug
efflux transporters, and low pinocytic activity [11, 12]) were used. The cell lines employed
included mouse immortalized brain microvessel endothelial cells (BMVEC), bovine brain
microvessel endothelial cells (BBMEC), and human epithelial colon carcinoma cells
(Caco-2). Brain microvessel endothelial cells from mouse, BMVEC, and bovine, BBMEC,
sources were used to evaluate species restrictions as they affected nanozyme transfers. In
addition, Caco-2 cells were investigated in transport studies based on their structural
integrity as compared to brain endothelial cells. The latter are presumed targets for transport
of free nanozyme and nanozyme loaded into macrophages.
Mouse BMVEC were isolated from mouse brains of 6–8 week old homozygous male
H-2Kb-ts-A58 mice (Immortomouse®, Charles River Labs) with slight modification [13].
Briefly, whole brains were removed, weighed and washed with Mince Buffer (HBSS,
amphotericin B [5.0 µg/mL], gentamicin [50 µg/mL], penicillin G [100 U/mL],
streptomycin sulfate [100 µg/mL]). The brains ∼1 mm sized fragments were incubated in
0.5% collagenase type 1 (Worthington Biochemical Corporation, Lakewood, NJ; 1 mL of
collagenase per g of whole brain) for 40 minutes at 37°C, and then centrifuged at 400g for
10 min. The pellet was washed 2X with 20% complete DMEM (DMEM, FBS 20% 1mM L-
glutamine, 2 mM Glutamax™, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids,
1X vitamins, 5.0 µg/mL amphotericin B [Fungizone™], 50 µg/mL gentamycin, 100 U/mL
penicillin G, 100 µg/mL streptomycin sulfate), filtered with a 70 µm nylon cell strainer (BD
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Falcon, Bedford, MA), spun at 400g for 10 minutes at 4°C, and cultured in 20% complete
DMEM at 33°C, 5% CO2 in flasks precoated with 1% gelatin. BMVEC were isolated from
heterogeneous populations of brain cells by FACS sorting after blocking with mouse BD Fc
block (BD Biosciences, San Jose, CA) and double staining for TNF-α-inducible (20 µg
murine TNF-α (Peprotech) / mL at 33°C for 4–6 hours), and for V-CAM-1/E-selectin
expression [13] using fluorescein rat anti-mouse CD106/VCAM1 (1.5 µg/1×106 cells; Clone
M/K-2: Southern Biotech, Birmingham, AL) and R-phycoerythrin rat anti-mouse CD62E/E-
Selectin/ELAM-1 (1.5 µg/1×106 cells; Clone 10E9.6: BD Biosciences, San Jose, CA).
Sorted cells were cultured in 6-well plates coated with 0.2% gelatin in DPBS and passaged
upon confluence up to passage 20. All procedures were approved by IACUC following
appropriate guidelines.
Bovine brain microvessel endothelial cell (BBMEC) were isolated from fresh cow brains by
enzymatic digestion and density centrifugation and grown until confluent (typically 12 days)
[14]. The BBMEC were maintained in MEM:F12 culture medium supplemented with 10%
horse serum, heparin sulfate (100 µg/mL), amphotericin B (2.5 µg/mL), and gentamicin (50
µg/mL). Human colon carcinoma (Caco-2) cell line was obtained from ATCC and cultured
in DMEM, containing 10% heat-inactivated FBS, 1% non-essential amino acids,
benzylpenicilin (100 U/ml) and streptomycin (10 µg/ml) [15].
Mouse catecholaminergic Cath.A neurons were purchased from American Type Culture
Collection (American Type Culture Collection, ATCC, Manassas, VA, USA) and cultured
in RPMI-1640 medium supplemented with 8% normal horse serum (NHS), 4% fetal bovine
serum (FBS), and 1% penicillin-streptomycin. Cath.A neurons were differentiated by adding
1 mM of N6,2’-O-dibutyryladenosine 3’,5’-cyclic monophosphate sodium salt (dbcAMP, St.
Louis, MO, USA) [16].
Astrocytes from rat brain frontal cortex tissue (CTX TNA2) were purchased from ATCC
and cultured in DMEM medium supplemented with 10% FBS, 4.5 g/L glucose, L-
glutamine, 110 mM sodium pyruvate, and 1% penicillin-streptomycin.
Alexa Fluor and Rhodamine Isothiocyanate (RITC) Labeled Catalase
Catalase was labeled with Alexa Fluor 594 or 647 Protein Labeling Kit (Molecular probes,
Inc., Eugene, OR, USA), or RITC [4]. Labeled catalase was purified from low molecular
weight residuals by gel filtration on a Sephadex G-25 column and lyophilized.
Catalase Nanozyme BMM Loading
BMM grown on T75 flasks (1–2 × 106 cells/flask) were pre-incubated with assay buffer
(122 mM NaCl, 25 mM NaHCO3, 10 mM glucose, 3 mM KCl, 1.2 mM MgSO4, 0.4 mM
K2HPO4, 1.4 mM CaCl2 and 10 mM HEPES), and then the cells were supplemented with
the fluorescently-labeled catalase nanozyme (Z =1, 0.5 mg/ml) in assay buffer for one hour
at 37°C [4]. After the incubation, the cells were washed three times with ice-cold PBS and
used in further experiments. The estimated levels of accumulated nanozyme were 25 µg/
1×106 cells.
Fluorescence Activated Cell Sorting (FACS)
Amount of fluorescently labeled nanozyme accumulated in target cells was measured by
FACS. Typically, monolayers of brain microvessel endothelial cells (BMVEC, or BBMEC),
Cath.A neurons, or astrocytes seeded in 6-well plates (1×106 cells/well) were allowed to
attach over night, and then incubated for various time intervals with BMM (1×106 cells/
well) loaded with catalase nanozyme or identical concentration of free nanozyme (without
BMM). To load BMM with nanozyme, the cell-carriers were incubated with catalase
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nanozyme (0.5 mg/ml, the highest non-toxic concentration of nanozyme) as previously
reported [5]. At these levels, one million BMM re-suspended in 1 ml of the media
accumulated 25 µg of nanozyme. The same concentration of free nanozyme was used to
compare nanozyme transferred from macrophages to endothelial and neural cells. Following
incubation, all cells were collected and the amount of nanozyme accumulated in the receiver
cells was assessed by FACS. To distinguish between the cell-carriers and target cells, BMM
were labeled with Alexa 678-conjugated Ab to CD 11b prior to the addition. To determine
whether cellular adhesion is required for nanozyme transfer, accumulation levels of RITC-
labeled nanozyme transferred from BMM to target BBMEC or neurons was assessed in the
presence of two adhesion inhibitors, trypsin (0.05%) or locostatin (50 µM). To evaluate
effect of energy depletion on nanozyme transfer from BMM, the target cells were pre-
incubated in glucose-free buffer with 50 mM 2-Deoxy-glucose (2-DG) and 150 µM NaN3
for one hour.
Confocal Microscopy
BMVEC and Cath.A neurons grown in the chamber slides [17] at a concenetration of 2×105
cells/chamber were co-cultivated with BMM loaded with RITC-labeled nanozyme (1×106
cells/chamber) and examined by a confocal fluorescence microscopy (ACAS-570 Meridian
Instruments, Okimos, MI, USA) with argon ion laser and corresponding filter set. Digital
images were obtained using the CCD camera (Photometrics) and Adobe photoshop
software. In some experiments cells nuclear were stained with DAPI (300 µM).
To confirm actual transport of catalase from macrophages to target cells, BMM were loaded
with non-labeled human catalase nanozyme, and added to BMVEC as described above.
Following incubation, the cells were fixed with 4% paraformaldehyde (PFA) for 15 min,
permeabilized with 0.4% Triton for 4 min, and stained with primary mouse Ab to human
catalase (Abcam #ab16772-100, Boston, MA, USA), and Alexa 567-conjugated secondary
goat anti mouse Ab (1:200 Dilution, Invitrogen, Carlsbad, CA, USA). Non-specific
interactions were blocked with 3% BSA for 30 min prior the staining with Ab. To
distinguish between the cell-carriers and receiver cells, BMM were labeled with Alexa 488-
conjugated Ab to CD 11b prior to the addition to receiver cells.
3H-labeled Nanozyme Permeability Studies
Confluent primary brain microvessel endothelial and epithelial cell monolayers retain
morphological and biochemical BBB characteristics [11]. The evaluation of monocyte [18]
and nanoparticle trafficking [19–21] across an in vitro BBB was investigated previously in
our laboratories. Herein, BBMEC or Caco-2 monolayers cultured in 12-well transwell
inserts with trans-epithelial electrical resistance (TEER) above 190 Ω ·cm2 or 220 Ω ·cm2
(for BBMEC and Caco-2, respectively) were used for transport studies. BMM loaded
with 3H-labeled nanozyme [4] were added in the upper chamber of BBMEC or Caco-2
monolayers at concentration of 1×106 cells/well. TNF-α (150 ng/ml, R&D Systems,
Minneapolis, MN, USA) was placed into the lower chamber and used as a chemoattractant
[18]. Free 3H-labeled nanozyme at identical concentration (25 µg/ml, 2.2 µCi/ml) was used
with control monolayers. Appearance of nanozyme in the receiver chamber was monitored
by radioactive count at various time intervals (0 – 360 min). All experiments were
performed in quadruplicate.
Antioxidant Activity Measurements
The ability of BMM loaded catalase nanozyme to scavenge hydrogen peroxide produced by
activated human blood monocytes was tested by Amplex Red. A linear dependence of the
catalytic activities on the enzyme concentrations was observed in the range of 0–1.0 mg/ml
[6]. Human monocytes seeded in 96-well plates at a concentration of 0.1 × 106 cells/well
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were stimulated with LPS, 20 ng/ml and IFN-γ, 2 µg/ml for 24 hours to induce ROS
production. Following incubation, the cells were supplemented with various concentrations
(5–50 µg/ml) of nanozyme loaded into BMM or nanozyme alone at the same concentrations
for another hour. Then cells were supplemented with Amplex Red Dye stock solution (10 U/
mL HRP, 10 mM Ampex Red) for 30 minute, and ROS content was measured by
fluorescence at λex=563 nm, λem=587 nm according to the manufacturer’s specifications.
Data represents ± SEM (n=4).
Statistical Analysis
For the all experiments, data are presented as the mean ± SEM. Tests for significant
differences between the groups were done using a one-way ANOVA with multiple
comparisons (Fisher's pairwise comparisons) using GraphPad Prism 5.0 (GraphPad
software, San Diego, CA, USA). A minimum p value of 0.05 was estimated as the
significance level for all tests.
RESULTS
Macrophage-facilitated Transport of Nanozyme to Target Cells
The transport of RITC-labeled catalase from carrier BMM to BMVEC, neurons, and
astrocytes, was examined. Given their involvement in the pathology of neurodegeneration,
these target cells represent potential sites for therapy. Target cells were incubated with
nanozyme alone or BMM loaded nanozymes at equivalent enzyme concentrations (25 µg/
mL) for 0.5 – 4.0 hours, and nanozyme concentrations in target cells were assessed by
FACS (Figure 1). Representative FACS plots are in supplementary material (Figure S1A).
Nanozyme transfer from BMM to all target cells (black bars) was greater than free
nanozyme (white bars), especially at later time points (Figure 1). Interestingly, mouse BMM
transferred nanozymes both syngeneically to mouse BMVEC (Figure 1A) and
xenogeneically to bovine BMVEC (Figure S1B), indicating no species restrictions.
A time course of RITC-labeled nanozyme transfer from BMM to BMVEC (Figure 2A,
Media S1) and Cath.A neurons (Figure 2B) was evaluated by confocal microscopy.
Nanozymes localized in BMVEC at the sites of contact with donor BMM (Figure 2A, B
shown by arrows). In contrast, free nanozymes diffused over the entire BMVEC monolayer
(Figure S2). For BMM-Cath.A, initiation at axonal sites was observed with BMM contact
that was followed by retrograde transfer of nanozymes into the neuronal cell body (Figure
2B, shown by arrows). Interestingly, no prolonged attachment of BMM to the target cells
was required for nanozyme transfer (Media S1).
To ensure the fluorescent staining reflected the intracellular localization of nanozyme and
not free fluorescent dye, inactive enzyme components, or cell surface associated nanozyme,
mouse BMM loaded with non-labeled human catalase nanozyme were incubated with mouse
BMVEC for two hours, fixed, permeabilized, and stained with primary Ab to human
catalase (Figure S3). Catalase accumulated in macrophages and in the BMVEC (shown by
arrows). No catalase was observed with non-permeabilized monolayers of nanozyme-loaded
BMM incubated with BMVEC, indicating that nanozyme was transferred inside the cells
and not onto the cell surface (data not shown).
Cell-Cell Contact and Adhesion for Nanozyme Transfers
Relationships between BMM and BMVEC cells were evaluated through accumulation of
RITC-labeled nanozyme from BMM with and without direct cell-cell contact (Figure 3A).
The substantial nanozyme transfer was recorded even without direct contact (Figure 3B),
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although, it was significantly greater when the contact between the donor and target cells
was allowed, indicating its importance for the efficient nanozyme transfer.
To determine whether cellular adhesion is required for nanozyme transfer, accumulation
levels of RITC-labeled nanozyme transferred from BMM to target BBMEC or neurons were
assessed in the presence or of absence two adhesion inhibitors, trypsin or locostatin.
Nanozyme transfers were not affected by the adhesion inhibitors (Table 1). Overall, rapid
movement of BMM and nanozyme administered to BMVEC (Media S1) support the idea of
transient cell-cell interactions during cell cultivation for up to two hours.
Transport of Nanozyme through Microtubules
It was demonstrated previously that macrophages infected with HIV-1 virus particles can
transfer them into uninfected cells through bridging conduits (BCs), filopodia and elongated
lamellipodia [22, 23]. These cytoskeleton components are essential for cytoplasmic
exchanges as well as cell signaling and migration. To this end, we examined involvement of
BCs in nanozyme transfer from BMM to target cells at > two hours (Figure 4). BMM loaded
with RITC-labeled nanozyme (red) formed multiple filopodia filled with nanozyme (Figure
4 A, B, shown by white arrows) that were stretched to the DIO-labeled BMVEC (green).
Human macrophages (green) formed elongated lamellipodia filled with nanozyme (red) over
the course of 18 hours (Figure S4). This suggests that the BCs connected cells and as such
facilitated nanozyme transfer. Partial co-localization of actin microfilaments and nanozyme
indicated involvement of microtubules network in nanozyme transfer (Figure 4 C–E).
Interestingly, two types of host cells were detected: i) transporting macrophages with strong
actin and nanozyme co-localization (Figure 4 C–E, shown by white arrows), and ii) resting
cells with very little co-localization (Figure 4 C and F, shown by green arrows). We posit
that membrane contacts of cell-carriers with the target cells may activate BMM and initiate
nanozyme transport by microtubules.
Transfer of Nanozyme Laden Lipids from BMM
We hypothesized that nanozymes are transferred to target cells with BMM components
including proteins or lipids. Thus, we assessed the possible involvement of lipid
compartments in cell-cell transfers of nanozymes by FACS and confocal microscopy
(Figures 5–7). Loaded with nanozyme and stained with DIO lipophilic dye BMM (Figure 5
A) were incubated with stained with DID Cath.A neurons (Figure 5 B). Substantial amount
of co-cultured cells carried both dyes after two hours of incubation (Figure 5 C and D).
Notably, lipid compartment transfer occurred from BMM to neurons but at an even greater
extent from neurons to BMM (Figure 5 D). Similar lipid exchange was observed for BMM-
BMVEC cell pair by confocal microscopy (Figure 6) showing vesicle-like inclusions with
BMM lipids (red) in BMVEC (Figure 6 A, B, shown by arrows), and BMVEC lipids (green)
in BMM (Figure 6 C, D). Corroborative evidence of concurrent transfer of nanozyme and
lipid compartments was obtained with BMM-neurons pair. Accumulation and co-
localization of BMM lipids (green) with nanozyme (red) in non-stained Cath.A neurons was
manifested by yellow staining (Figure 7, shown by arrows). Overall, the data suggests that
nanozyme was wrapped into lipids from BMM, which increased membranotropic properties
and facilitate nanoparticle transfer amongst the cells.
To test this, accumulation levels of freshly prepared or released from BMM nanozyme were
compared in Cath.A neurons (Figure 8 A). Transfer of nanozyme released from BMM was
significantly greater than freshly prepared nanoparticles (Figure 8 B) confirming its
facilitated transport from BMM to co-cultured target cells.
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Effect of Energy Depletion on Nanozyme Cell Transfer
Proteins and nanoparticles, such as nanozymes, accumulate in cells predominantly by
endocytosis, an ATP-dependent process. To determine whether this mechanism is involved
in the BMM-mediated nanozyme transfer, accumulation levels of free or loaded in BMM
nanozyme in target cells (BMVEC, BBMEC, and Cath.A neurons) was assessed under
homeostatic conditions or at energy-depletion state. Accumulation of free nanozyme was
significantly decreased by ATP depletion in the target cells (Table 2). In contrast, nanozyme
transport from BMM was unaffected suggesting that this process is endocytosis-
independent. Both bovine and mouse BMVEC showed identical mechanism, re-affirming
that nanozyme transfer is not species specific.
BMM-mediated Transfer of Nanozyme in an Artificial BBB Model
Given the obtained data, we hypothesized that nanozyme facilitated transfer to BMVEC
from BMM might result in improved BBB penetration compared to free nanozyme. BBMEC
[11] and Caco-2 [12] monolayers that exhibit BBB functional properties, were used to test
this hypothesis. Transport of nanozyme loaded into BMM was substantially greater than free
nanozyme in both systems (Figure 9 A, B). The advantage of cell-mediated transfer was
even more evident in Caco-2 in vitro model, probably, due to the fact that the epithelial cell
monolayers are less leaky than BBMEC (see Materials and Methods section).
Antioxidant Activity of Nanozymes
Given facilitated nanozyme transfer from BMM, it may eliminate ROS more efficiently than
free nanozyme. Human monocytes stimulated with lipopolysacharide (LPS) and interferon
gamma (IFN-γ) were used to test this hypothesis. This reflects, in part, the inflammatory
environment that blood borne brain macrophages and microglia find themselves in during
progressive neurodegenerative diseases such as PD. Following activation, the cells were
supplemented with various concentrations of free nanozyme or nanozyme loaded into BMM
(Figure 9 C). Quiescent monocytes (unactivated, first bar) or LPS/IFN-γ activated cells
without subsequent treatment with nanozyme (second bar) were used as a control.
Nanozyme loaded in BMM has greater antioxidant activity than the identical concentrations
of free enzyme (Figure 9 C), probably, due to the facilitated transport of nanozyme from
macrophages to the adjacent target cells.
DISCUSSION
The ability to communicate between cells is crucial for the survival of large multicellular
organisms as it allows coordinating their functional activities at the organ level. Divergent
types of cells show exchange of organelles and endogenous molecules between one other.
The most known example is a transfer of neurotransmitters in neurons [24]. Cell-to-cell
exchange of viral particles was reported in plants [25] and eukaryotic cells [26, 27]. In
particular, it was demonstrated that HIV-1 spreads from uninfected to infected cells through
bridging conduits mediated by endocytic trafficking [22, 23]. Importantly, this transport
occurs in non-degraded cargoes caring functionally active viral constituents capable of
proviral integration and expression in the target uninfected cells. This adverse mechanism of
viral dissemination that shelters HIV-1 providing systemic infection and disease progression
may play positive role in case of cell-mediated drug delivery, where preservation of
enzymatic activity of the drug (herein catalase) in the cell-carriers is crucial.
Macrophages were already shown to serve as vehicles for nanoformulated antiretroviral drug
delivery [28–30]. Additional works indicated that they may also be harnessed for therapeutic
use for a range of CNS disorders, such as HIV-associated neurocognitive disorders,
cerebrovascular diseases, and neurodegenerative disorders, AD and PD [9, 31–33]. In this
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respect to improve drug transport across the BBB, we developed a new drug delivery system
using specific cells-carriers that can incorporate nanocontainers loaded with drugs and act as
perfect Trojan horses migrating across the BBB to deliver drugs to sites. Indeed, MPs loaded
with catalase nanozyme can attenuate neuroinflammation and neurodegeneration in models
of PD [4, 5]. The present work developed new insights into how the cell-carriers can yield
superior clinical results from nanoparticles administered alone. This involves facilitated
transfer of drug-loaded nanoparticles from MPs to target cells that are intimately involved in
the development of neurodegenerative disorder itself such as BMVEC, neurons, and
astrocytes.
We report here for the first time to the best of our knowledge that macrophages, loaded with
nanozyme, promote its accumulation in the target cells indicated above. Interestingly,
increased transfer was observed for the same species donor-receiver cell pair (C57Bl/6
mouse), as well as for different hosts cell pairs (mouse-rat, mouse-bovine, and mouse-
human). Staining with fluorescently-labeled Ab to catalase confirmed the intercellular
transfer of nanozyme and not free fluorescent dye, inactive enzyme components or cell
surface associated nanozyme. The dynamic of nanozyme cell-to-cell transfer revealed initial
localized distribution of nanozyme in the receiver cells at the sites of their contact with the
donor BMM, in contrast, free nanozyme that diffused over entire cell monolayer. Retrograde
transfer of nanozymes from BMM initiated at the axon site was observed in the neuronal cell
body.
Cell-to-cell contact plays an important role in this transfer, although, no prolonged
attachment of BMM to the target cells was required for nanozyme transfer. Thus,
macrophages placed on the top of BMVEC monolayers transferred significantly greater
amount of nanozyme compared to the same amount of cell-carriers localized in 2–4 mm
above the target cell. Nevertheless, adhesion of macrophages onto the receiver cells is not
required for the successful transfer of nanozyme at least for the first two hours of incubation.
In particular, target cells (BMVEC or neurons) that were pre-incubated with adhesion
inhibitors, trypsin or locostatin, accumulated the same amount of nanozyme as the cells in
the absence of the inhibitors. It is likely that that partial transient fusion of the cell
membranes is involved in this transfer.
Over longer time periods (2–18 hours), the loaded macrophages developed filopodia and
lamellipodia filled with nanozyme that was involved in cell-to-cell drug transfer.
Interestingly, confocal images revealed two types of cell-carriers: i) “transporting”
macrophages with strong co-localization of nanozyme and actin microfilaments, and ii)
“resting” macrophages where nanozyme is stored in intracellular compartments distinct
from BCs. We speculate that macrophages coming in contact with the target cells become
activated and initiate nanozyme transfer using actin microphilaments as tracks.
Nanozyme was transferred along with lipids from cell-carriers. A strong co-localization of
fluorescently-labeled nanozyme and lipids of the BMM was demonstrated in BMVEC and
neuron targets. In fact, we do not exclude that nanozyme might be transported along with
whole lipid and protein-containing compartments from macrophages into target cells. Such
“coating” should increase membranotropic properties and facilitate intracellular transport of
nanozyme. To separate this process from the nanozyme transfer through the transient
membrane fusion, the accumulation levels of nanozyme released from BMM was compared
with the fresh prepared nanozyme. Accumulation of nanozyme released from BMM was
significantly greater than fresh prepared nanozyme. It signifies that the observed facilitated
nanozyme transfer may be, in part, due to the nanozyme lipid coating and subsequent biding
with the lipid membranes of the target cells. We hypothesized that such coating may occur
when nanozyme is released from BMM in exosomes. The similar phenomenon was reported
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for virus particles [34]. In fact, nanozyme transfered through transient membranes fusion
and BCs formation may also be incorporated in such compartments.
All above mentioned mechanisms may completely change the mechanism of nanozyme
entry in the receiver cells. Indeed, intercellular nanozyme transfer was not affected by
energy depletion in the target cells, suggesting that neither the cell-to-cell transfer by
transient membrane fusion or developing filopodia and lamellipodia, nor the transfer of
lipid-coating of nanoparticles involves endocytosis.
The observed phenomena may have significant therapeutic outcomes. Specifically,
nanozyme-loaded BMM efficiently transfer nanoparticles into BMVEC may facilitate their
delivery to the brain parenchyma enhancing BBB permeability and CNS drug transport.
Furthermore, drug-loaded cell-carriers reaching the inflamed brain areas may infuse/unload
active nanozyme into neurons, astrocytes or microglial cells with efficient ROS
decomposition and subsequent reduction of inflammation. Indeed, enhanced transport of
nanozyme from cell carriers compared to free nanozyme across BBB in vitro was
demonstrated. Nanozyme facilitated transfer resulted in efficient ROS decomposition in
activated human monocytes that served as a model of microglial activation.
Previously, we suggested three different mechanisms that may singly or collectively be
responsible for improved therapeutic effects of nanozyme loaded into macrophages in
mouse PD model (Figure 10) [5]. First, BMM loaded with catalase might reach CNS
inflammation site and deliver catalase, i.e. accomplish targeting delivery of catalase to
SNpc. Second, nanozyme-loaded BMM might work as a depot for the sustained release of
nanoformulated catalase in vivo, when the enzyme enters the brain independently of cell-
carriers. In fact, we demonstrated that some portion of loaded macrophages migrates from
the blood away into the tissue and the tissue-associated BMM slowly unload nanozyme and
supply the blood plasma with sustained levels of catalase. Third, catalase released from cell-
carriers in the liver or spleen (the most enriched organs after transfer of nanozyme-loaded
BMM) and produced suppression of peripheral leukocyte activation resulting in significant
protection of nigrostratial neurons against MPTP-induced neurodegeneration. The facilitated
transfer of nanozyme from the cell-carriers into BMVEC, neurons, and astrocytes, reported
here, is an additional fourth mechanism. While multiple mechanisms may play roles in
neuroprotective effects of nanozymes, cell to cell transfer may be the mechanism that
coordinates other mechanisms to strengthen the final therapeutic effect.
CONCLUSIONS
The numbers of cell-carriers that can reach the disease site is crucial in the case of CNS
disorders, when drug needs to be delivered cross the BBB to mediate therapeutic effect. In
fact, many neurological diseases, such as Alzheimer’s and Parkinson’s diseases, Prion
disease, meningitis, encephalitis and AIDS related dementia, have in common an
inflammatory component [35] characterized by extensive immunocyte recruitment to the
brain. Based on the cells’ presence within the central nervous system during disease, they
can reach the brain after peripheral loading with nanoparticles. Nevertheless, nanozyme
facilitated transfer from BMM to neural cells, in particular, BMVEC, suggests that drug
transport can be accomplished without actual crossing the BBB but through the promoted
transport of nanozyme from BMM. This involved fusion of cellular membranes;
macrophage bridging conduits; and nanozyme lipid coatings. Such cell-to-cell activites may
also improve efficiency of reactive oxygen species (ROS) decomposition by catalase
nanozyme in neurons and astrocytes.
EXECUTIVE SUMMARY
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• This study, to the best of our knowledge, is the first demonstration of
nanoparticular catalase facilitated transport from macrophages into three types
of target cells: brain microvessel endothelial cells, neurons, and astrocytes, was
demonstrated.
• Cell-to-cell contact between macrophages and receiver cells increases nanozyme
transfer, although no adhesion is required.
• Nanozyme transfer occurs through partial transient fusion of donor and receiver
cells at shorter time points, or through formation of filopodia and lamellipodia
after longer exposure times.
• Nanoparticles are transferred along with lipids from host cells that increased
their membranotropic properties and facilitated transport into the target cells.
• Facilitated transport of nanozymes from BMM into target cells occurs through
an endocytosis-independent pathway.
• Facilitated transport of nanozyme results in improved penetration across the
BBB and ROS dismutation in vitro.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Intercellular transport of nanozyme from BMM to endothelial and neural cells
RITC-labeled nanozyme were loaded to BMM (black bars) or nanozyme were administered
alone (white bars) to A, murine BMVEC; B, CATH.a transformed neurons; or C, rat
astrocytes for 0.5 to 4 hours. Following incubation, BMM were stained with CD11b Ab
(Alexa 488) and the amount of nanozyme that was accumulated in CD11b-negative recipient
cells (endothelial cells, neurons or astrocytes) assessed by FACS as mean RITC
fluorescence ± SEM (n=4). Nanozyme transfers from BMM to each of the recipient target
cells were greater in BMM laden nanozyme co-cultures (black bars) than with free
nanozyme (white bars). Significance of BMM nanozyme vs. free nanozyme at each time
point is shown by asterisk (**p<0.005).
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Figure 2. Kinetic transport of nanozymes from BMM to endothelial cells and neurons
Confocal images of murine BMVEC (A) or Cath.A neurons (B) incubated with BMM
loaded with RITC-labeled catalase nanozyme (red). BMM were labeled with Alexa 678-
conjugated Ab to CD 11b (green). Co-localization of nanozyme (red) and BMM CD 11b
staining (green) was manifested in yellow. The last time point fluorescence image of each
set is shown with DIC. Nanozymes were transferred from BMM to BMVEC (A) or from
BMM to neurons (B) at the sites of cell contact with donor cells (shown by arrows). The
initiation at the axon sites was observed upon contact with BMM followed by retrograde
transfer of nanozymes into the neuronal cell body (B). Bar = 20 µm.
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Figure 3. Cell-cell contact facilitate nanozyme transfer from BMM to BMVEC
BMVEC were grown on the bottom of the plate. BMM stained with DID (green) were
loaded with RITC-labeled nanozyme (red) and placed: i) on top of BMVEC (contact), or ii)
∼two mm above the BMVEC (no contact). In case of “no contact”, BMM were attached to a
semi-permeable membrane and located on the down side of the membrane. Following a two-
hour incubation, the cells were collected and the amount of nanozyme accumulated in the
recipient cells assessed by FACS. A, experimental scheme; B, average RFU ± SEM (n=3)
demonstrating significantly greater nanozyme levels when BMM were in contact with
recipient cells and demonstrating the importance of cell-cell communications for nanozyme
transfer. Statistical significance was calculated between cell-cell contact vs. no cell contact
(**p<0.005).
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Figure 4. Transfer of nanozyme from BMM to BMVEC is facilitated by BCs
BMM were loaded for 2 hrs with RITC-labeled nanozyme (red), and then co-cultured with
DIO-labeled (A, B, green) or non-labeled BMVEC (C–F) for 18 hours. C–F, After
incubations cells were fixed, permeabilized and stained with Alexa488-labeled phalloidin to
visualize actin filaments (green). Cell nuclei were stained with DAPI. BMM contained
multiple filopodia filled with nanozymes (A, B white arrows) supporting their involvement
in nanoparticles transfer. Actin microfilaments staining (C–F) revealed macrophages in two
different stages: i) transporting macrophages with actin and nanozyme co-localization
(Figure 4 C–E, shown by white arrows); and ii) resting macrophages with limited co-
localizations (Figure 4 C and F, shown by red arrows). Bar represents 20 µm.
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Figure 5. Intercellular exchange of BMM and neuronal lipid compartments
BMM loaded with nanozyme were stained with Alexa 678-conjugated Ab to CD 11b, then
incubated with Cath.A neurons stained with DID lipophilic dye. These were performed at
37°C for two hours. Following incubation, percentage of cells which accumulated both dyes
were assessed by FACS: A, Cath.A neurons stained with DID; B, BMM loaded with
nanozyme and stained with Alexa 678; C, Incubation of Cath.A neurons and BMM; D,
Quantification of label exchange is shown. Results from N=4 wells (± SEM) demonstrate
that Cath.A neurons and BMM (at greater extent) exchange membrane dyes. Statistical
significance is shown by asterisk: p<0.005 (**) compared to what was observed before
incubation.
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Figure 6. Intercellular exchange of BMM and BMVEC lipid compartments
BMM loaded with nanozyme were stained with DID dye (red) and incubated with BMVEC
stained with DIO dye (green), Cells were cultivated one with the other at 37°C for two hrs.
Following incubation cells co-cultures were washed with PBS and visualized by confocal
microscopy. A, C, fluorescent images only; B, D, fluorescent images with DIC are shown.
Images demonstrated presence of red vesicles from BMM in BMVEC cells (A, B), and
green vesicles from BMVEC in BMM (C, D) pointed with arrows. Bar represents 20 µm.
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Figure 7. Transfer of nanozyme along with lipid compartments from BMM to neurons
RITC-labeled nanozyme (red) was loaded into BMM labeled with DIO (green), and added
to Cath.A neurons. Following a two-hour incubation, the cells were washed with PBS then
visualized by confocal microscopy. A, C, fluorescent images only; B, D, fluorescent images
with DIC. Images show red nanozyme co-localized with green vesicles (lipids) from BMM
in Cath.A neurons. These are seen by arrows. Bar represents 20 µm.
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Figure 8. Facilitated transport of nanozyme released from BMM to neurons
Loaded with 3H-labeled catalase nanozyme BMM were incubated in assay buffer for at
37°C for two hrs. Nanozyme released into the media was collected then added to Cath.A
neurons for an additional two hrs. In parallel, neurons were incubated with freshly prepared
nanozyme (at the same concentration) as a control. Following incubation cells were
collected and the amount of accumulated nanozyme assessed by a liquid scintillation
counting. A, overall experimental scheme; B, Results from N=4 wells (± SEM)
demonstrated that nanozyme released from BMM accumulated in neurons at greater levels
than freshly prepared nanozyme. Statistical significance is shown by asterisk: p<0.05 (*).
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Figure 9. BMM-mediated transfer of nanozyme to endothelial cells and neurons
Effect of nanozyme loading into BMM on its transport across BBB in vitro (A, B), and its
antioxidant activity in human monocyte-derived ROS (C). A, B, 3H-labeled nanozyme
loaded into BMM (filled diamonds), or nanoparticles alone (empty squares) were added to
the donor (upper) chamber with A, BBMEC monolayers; or B, Caco-2 monolayers. Aliquots
from the receiver (lower) chamber were taken at different time points and radioactivity was
recorded. C: Blood human monocytes were stimulated with LPS (20 ng/ml) and IFN-γ (2
µg/ml) for 24 hours. Then the cells were supplemented with: various concentrations of free
nanozyme (third group) or nanozyme loaded into BMM (fourth group). A concentration of
nanozyme in the media added to the activated monocytes varied from 0 to 50 µg/ml. Control
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non-activated BMM (first bar) or activated BMM without subsequent treatment with
nanozyme (second bar) were incubated with fresh media. Following incubation, the cell
media was supplemented with Amplex Red and HRP solutions. Amount of H2O2 produced
by BMM and decomposed by catalase nanozymes after 90 min was detected by
fluorescence. Results from N=4 wells (± SEM) clearly demonstrated that nanozyme
transport across an in vitro BBB (A and B), and the enzymatic activity of nanozymes (C)
from the cell-carriers was substantially greater, compared to the transport and activity of free
nanozyme. Statistical significance is shown by asterisks: (*) p<0.05, and (**) p<0.005. For
antioxidant activity studies (C) statistical significance was compared with: a) activated cells,
and b) non-activated BMM.
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Figure 10. A pictorial scheme for cell-based nanoformulated drug delivery
Four possible ways of BMM-mediated therapeutic effects of catalase nanozyme in PD
mouse model: Pathway I: BMM loaded with nanozyme cross the BBB and release catalase
in SNpc; Pathway II: nanozyme is released from BMM to the blood stream and bypass the
BBB independently of cell-carriers; Pathway III: BMM released catalase nanozyme in the
liver and spleen suppressing peripheral leukocyte activation that may result in decrease of
inflammation in the brain; Pathway IV: loaded with nanozyme BMM interact with the
target cells and facilitate transfer of nanozyme from the cell-carriers into brain MVEC,
neurons, and astrocytes.
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Table 1
Effect of adhesion inhibitors on nanozyme transfer from BMM into target cells
Target Cells Trypsin, % of control * Locostatin, % of control *
BBMEC 118± 5 (n.s.) 99 ± 5 (n.s.)
Cath.A neurons 115 ± 4 (n.s.) 110 ± 5 (n.s.)
*
Accumulation levels of nanozyme are calculated as a percentage of those treated in the absence of the adhesion inhibitors.
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Table 2
Effect of energy depletion on nanozyme transfer from BMM to target cells
Target Cells Nanozyme-loaded BMM,
% of control *
Free nanozyme,
% of control *
BMVEC 102 ± 5 (n.s.) 51 ± 2 (**)
Cath.A neurons 101 ± 4 (n.s.) 37 ± 5 (**)
BBMEC 100 ± 3 (n.s.) 49 ± 2 (**)
*
Accumulation levels of nanozyme are calculated as a percentage of those in control cells treated in assay buffer with glucose in the absence of
inhibitors of ATP synthesis (50 mM 2-DG and 150 µM sodium azide).
Statistical significance compared to accumulation levels in assay buffer with glucose is shown by asterisk: p<0.005 (**).
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